Balchem Corporation — Q1 2013 Form 10-Q
Reporting period: Three months ended March 31, 2013; comparisons are with Q1 2012 unless noted. Balchem develops and sells specialty ingredients and products for food, nutrition, pharmaceutical, animal health, and medical-device sterilization markets. Dollar amounts below are in millions unless stated otherwise.
Financial performance
| Metric | Q1 2013 | Q1 2012 | Change |
|---|---|---|---|
| Net sales | $84.651 | $76.203 | +11.1% |
| Gross profit | $24.232 | $21.158 | +14.5% |
| Gross margin | 28.6% | 27.8% | +0.8 percentage points |
| Operating income | $15.865 | $13.675 | +16.0% |
| Operating margin | 18.7% | 17.9% | +0.8 percentage points |
| Net earnings | $10.888 | $9.268 | +17.5% |
| Diluted EPS | $0.36 | $0.31 | +$0.05 |
Revenue growth and improved margins reflected higher volumes, operating efficiencies, and lower costs for certain raw materials. Operating expenses rose 11.8% to $8.367 million, driven mainly by employee and compensation costs, professional fees, marketing, and relocation expense. The effective tax rate declined to 31.4% from 32.3%, primarily due to timing of certain tax credits.
Segments and material changes
| Segment | Sales, Q1 2013 | Year-over-year sales growth | Segment operating earnings, Q1 2013 |
|---|---|---|---|
| Specialty Products | $12.780 million | 4.3% | $4.909 million |
| Food, Pharma & Nutrition | $11.008 million | 2.5% | $2.507 million |
| Animal Nutrition & Health | $60.863 million | 14.4% | $8.449 million |
Animal Nutrition & Health contributed most of the sales increase, with higher specialty-ingredient and feed-grade choline volumes and increased industrial sales, including fracking-related demand. Industrial applications were approximately 32% of this segment’s sales. Growth was partly offset by the previously announced suspension of AminoShure-L 52% lysine sales. Food, Pharma & Nutrition earnings declined 7.5%, mainly because of higher raw-material costs; lower human choline sales also partly offset segment sales growth. Specialty Products sales benefited from industrial propylene oxide volumes and ethylene oxide products.
Cash flow, liquidity, and balance sheet
- Cash and cash equivalents were $149.090 million at March 31, 2013, versus $144.737 million at December 31, 2012. Working capital was $195.570 million, up from $181.675 million.
- Operating cash flow was $4.353 million, down from $12.655 million in Q1 2012. Management attributed the decline chiefly to less favorable working-capital movements, including receivables, inventory, payables/accruals, and income taxes.
- Capital expenditures were $3.400 million, versus $1.401 million; most Q1 2013 spending related to the new Covington, Virginia manufacturing facility. Cash flow after capital expenditures was approximately $0.953 million.
- Total liabilities were $34.992 million; current liabilities were $26.366 million. The company reported no borrowings at March 31, 2013. Interest expense was $0.001 million.
- Financing cash flow included $2.097 million in stock-option proceeds and $1.491 million in excess tax benefits. No dividends were paid in Q1 2013, compared with $5.237 million in Q1 2012.
Outlook, risks, and contingencies
No quantified earnings or revenue guidance was provided. Management expects operating cash generation to fund working-capital needs and necessary capital investments, and said it is pursuing acquisition candidates; it may use bank loans or capital markets if needed. Management emphasized plant efficiency, volume growth, broader product applications, and leveraging choline production capabilities. Q1 results are not necessarily indicative of full-year results.
Risks include foreign-exchange movements and commodity/raw-material price exposure; the company says it manages these primarily through pricing and operational measures and had no derivatives. The filing reports ongoing discussions with New York regulators regarding possible further monitoring at a former buried-drum site; historical monitoring costs were less than $5,000 annually. A former-owner Superfund matter at the Verona facility remains subject to agency review; the company says remediation is complete and describes seller indemnification. Management did not expect litigation, claims, or assessments to materially affect financial position, results, or liquidity. Operating lease minimum payments totaled $4.103 million. Unrecognized tax benefits were approximately $2.5 million, with no material change anticipated over the next 12 months. No material changes to the 2012 Form 10-K risk factors were reported.
Important facts for investors to verify
- Whether the lower operating cash flow reflects temporary working-capital timing or a continuing cash-conversion trend.
- Progress, spending, and expected completion of the Covington facility investment.
- Durability of Animal Nutrition & Health growth, including industrial/fracking demand and the AminoShure-L sales suspension.
- Whether raw-material costs, foreign exchange, or pricing changes affect margins, particularly in Food, Pharma & Nutrition.
- Updates on environmental matters, tax positions, and any acquisition plans or financing needs.